This resource accompanies the Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard. It describes what the quality statements mean for healthcare services and provides indicators to support local quality improvement activity.

Psychotropic medicines are commonly prescribed to people with cognitive disability or impairment, including older people with dementia and people of all ages with intellectual disability, autism spectrum disorder and other neurodevelopmental conditions. Psychotropic medicine use in these populations is disproportionately high, reflecting a...

A literature review for updating the National Consensus Statement: Essential elements for safe and high-quality end-of-life care beyond acute care and during a pandemic.

This resource outlines what antimicrobial resistance (AMR) is, and how we need to limit our use of antimicrobials – such as antibiotics, antivirals, antifungals and antiparasitics – to reduce the risk of drug-resistant infections and impact of AMR. It also outlines potential patient harms to the individual and the broader community from...

A list of members in the Topic Working Group supporting the development of the clinical care standard aiming to reduce inappropriate use of psychotropic medicines for behaviour.

On 27 August 2021, the Commission released the Fourth Australian report on antimicrobial use and resistance in human health (AURA 2021).

On 9 September 2021, the Commission released the updated Delirium Clinical Care Standard (2021).

We are pleased to announce that registrations are now open for the National Medicines Symposium 2024.

The full program for the National Medicines Symposium 2024 is live.

There's still time to secure your place at the National Medicines Symposium on 19 November 2024.